How I treat newly diagnosed chronic phase CML

Blood. 2012 Aug 16;120(7):1390-7. doi: 10.1182/blood-2012-03-378919. Epub 2012 May 21.

Abstract

The progress made in the understanding of chronic myeloid leukemia (CML) since the recognition of a common chromosomal abnormality to the introduction of ever more effective tyrosine kinase inhibitors is unprecedented in cancer. The expected survival for patients diagnosed with CML today, if properly managed, is probably similar to that of the general population. When managing patients with CML the goal is to achieve the best long-term outcome and we should base the treatment decisions on the data available. The results from cytogenetic and molecular analyses have to be interpreted judiciously and all available treatment options integrated into the treatment plan properly. The availability of several treatment options in CML is an asset, but the temptation of rapid succession of treatment changes because of perceived suboptimal response or for adverse events that could be managed needs to be avoided. Any decision to change therapy needs to weigh the expected long-term outcome with the current option versus the true expectations with any new option, particularly as it relates to irreversible outcomes, such as transformation to blast phase and death. In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population.

Publication types

  • Review

MeSH terms

  • Cytogenetic Analysis
  • Humans
  • Leukemia, Myeloid, Chronic-Phase / diagnosis*
  • Leukemia, Myeloid, Chronic-Phase / genetics
  • Leukemia, Myeloid, Chronic-Phase / pathology
  • Leukemia, Myeloid, Chronic-Phase / therapy*
  • Neoplasm Staging
  • Risk Factors
  • Withholding Treatment